Anebulo Pharmaceuticals Ownership

ANEB Stock  USD 2.38  0.01  0.42%   
Anebulo Pharmaceuticals holds a total of 41.08 Million outstanding shares. Over half of Anebulo Pharmaceuticals' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Anebulo Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Anebulo Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anebulo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in banks.
For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.

Anebulo Stock Ownership Analysis

About 41.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.25. Anebulo Pharmaceuticals had not issued any dividends in recent years. Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. The company was incorporated in 2020 and is based in Lakeway, Texas. Anebulo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. For more info on Anebulo Pharmaceuticals please contact Richard Cunningham at 512 598 0931 or go to https://www.anebulo.com.

Anebulo Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anebulo Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anebulo Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anebulo Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Aryeh Jason over two months ago
Acquisition by Aryeh Jason of 4964 shares of Anebulo Pharmaceuticals at 1.02 subject to Rule 16b-3
 
English Aron R. over three months ago
Acquisition by English Aron R. of 300000 shares of Anebulo Pharmaceuticals subject to Rule 16b-3
 
Calloway Nathaniel over three months ago
Acquisition by Calloway Nathaniel of 25000 shares of Anebulo Pharmaceuticals at 1.02 subject to Rule 16b-3
 
Kupchyk Areta over three months ago
Acquisition by Kupchyk Areta of 2647 shares of Anebulo Pharmaceuticals at 1.02 subject to Rule 16b-3
 
Gardiner Sandra A. over six months ago
Insider Trading
 
Cunningham, Richard Anthony over six months ago
Acquisition by Cunningham, Richard Anthony of 254433 shares of Anebulo Pharmaceuticals at 1.56 subject to Rule 16b-3
 
Allen Simon over six months ago
Acquisition by Allen Simon of 70246 shares of Anebulo Pharmaceuticals subject to Rule 16b-3
 
Cunningham, Richard Anthony over six months ago
Acquisition by Cunningham, Richard Anthony of 254433 shares of Anebulo Pharmaceuticals at 1.56 subject to Rule 16b-3
 
Kupchyk Areta over six months ago
Disposition of 82290 shares by Kupchyk Areta of Anebulo Pharmaceuticals at 2.18 subject to Rule 16b-3
 
English Aron R. over six months ago
Acquisition by English Aron R. of 714250 shares of Anebulo Pharmaceuticals at 7.0 subject to Rule 16b-3
 
Allen Simon over a year ago
Insider Trading
 
Aryeh Jason over a year ago
Acquisition by Aryeh Jason of 2482 shares of Anebulo Pharmaceuticals at 2.1 subject to Rule 16b-3

Anebulo Pharmaceuticals Outstanding Bonds

Anebulo Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Anebulo Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Anebulo bonds can be classified according to their maturity, which is the date when Anebulo Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anebulo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in banks.
For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.